{
    "nct_id": "NCT03575819",
    "official_title": "A Phase 1 Study of FOR46 Administered Every 21 Days in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
    "inclusion_criteria": "* Male ≥ 18 years of age\n* Has histologically confirmed prostate cancer that is metastatic and has progressed as defined by PCWG3 criteria during or after treatment with at least 1 ASI (eg, abiraterone, enzalutamide, apalutamide), or another second-generation anti-androgen or cytochrome P450 (CYP)17A1 inhibitor, with the most recent ASI administered in the castration-resistant setting\n* Has serum testosterone levels < 50 ng/dL during screening. Patients without a history of bilateral orchiectomy are required to remain on luteinizing hormone-releasing hormone (LHRH) analog during the course of protocol therapy\n* ECOG performance status of 0 or 1\n* Adequate hematologic, renal and hepatic function\n* Males with female partners of childbearing potential must agree to use 2 effective methods of contraception\n* Patients must provide signed informed consent\n* Patients enrolled into the dose expansion phase must have prostate carcinoma without histologic evidence of small-cell/neuroendocrine carcinoma features on prior biopsy or must have unequivocal histologic evidence of small-cell/neuroendocrine prostate carcinoma (pure or mixed). Patients with treatment-emergent small-cell neuroendocrine cancer (pure or mixed) may have received no more than on prior chemotherapy regimen for mCRPC\n* Patients enrolled into the dose expansion phase must be willing to undergo a metastatic tumor biopsy or has tissue available from a prior post-castration resistant tumor biopsy\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Persistent clinically significant toxicities from previous anticancer therapy\n* Has NCI CTCAE Grade ≥ 2 peripheral neuropathy from any etiology or has a genetic disorder that is associated with peripheral neuropathy even without current neuropathic manifestations\n* Prior treatment with cytotoxic chemotherapy for mCRPC (chemotherapy in the hormone-sensitive setting is allowed if > 6 months before study entry)\n* Has received external-beam radiation or systemic anticancer therapy within 14 days before first dose of FOR46\n* Has received treatment with an investigational drug within 28 days before first dose of FOR46\n* Has had a major surgical procedure within 28 days before administration of FOR46 dose\n* Clinically significant cardiovascular disease\n* Uncontrolled, clinically significant pulmonary disease\n* Has a history of brain or leptomeningeal metastases.\n* Uncontrolled intercurrent illness\n* Has a known positive status for HIV or either active/chronic hepatitis B/C\n* Requires medications that are strong inhibitors or strong inducers of CYP3A4\n* [Dose escalation only] Has a history of episodic atrial fibrillation or flutter (patients with chronic atrial fibrillation are not excluded)",
    "miscellaneous_criteria": ""
}